New Open Access Journal Will Advance Engineering And Opportunities In Translational Medicine

AIChE and Society for Biological Engineering join forces with Wiley to launch Bioengineering & Translational Medicine, with Samir Mitragotri of the University of California, Santa Barbara, as editor-in-chief.

Oct 14, 2015, 12:52 ET from American Institute of Chemical Engineers

NEW YORK, Oct. 14, 2015 /PRNewswire/ -- The American Institute of Chemical Engineers (AIChE) and its Society for Biological Engineering (SBE), in partnership with John Wiley and Sons, are launching a new quarterly, peer-reviewed, online, open-access journal, Bioengineering & Translational Medicine, in 2016. To be part of the Wiley Open Access portfolio and edited by Samir Mitragotri of the University of California, Santa Barbara, the new journal will focus on ways chemical and biological engineering are driving innovations and solutions that impact clinical practice and commercial healthcare products. The journal will also highlight scientific and technical breakthroughs currently in the process of clinical and commercial translation.

In announcing Bioengineering & Translational Medicine, AIChE Executive Director June Wispelwey said that the new journal represents "one of the latest and most significant examples of the strengths that chemical and biological engineers bring to the frontiers of inter-disciplinary research and its application." She added that she was excited that the journal attracted "such an esteemed editor in Dr. Mitragotri, and a very, very distinguished editorial advisory board."

In discussing his plans for the journal, Mitragotri said, "Converting engineering advances into useful clinical products is a major challenge that requires attention to issues such as safety, manufacturability, regulatory hurdles, cost, and patient acceptance, among others." These issues, he pointed out, are not typically considered in fundamental academic research. "Clinical translation also often needs concurrent consideration of commercial translation, with the team and the resources required for clinical translation often assembled during commercial translation," he explained. He added that this interplay presents its own set of challenges.

Bioengineering & Translational Medicine welcomes manuscripts that provide new insights into translational hurdles, as well as examples of technologies that have demonstrated progress toward clinical or commercial translation. It invites contributions on topics including, but not limited to, drug delivery, drug discovery, tissue engineering, synthetic biology, gene therapy, computational modeling and bioinformatics, among others. (A more comprehensive list of topics can be found in the journal's statement of scope.) The journal will include research reports, reviews, and rapid communications. Fully open access Bioengineering & Translational Medicine will be published under CC-BY license.

Mitragotri concluded: "To researchers who are active, or aspiring to be active, in clinical and commercial translation of biological technologies, I say 'this is your journal.' With a stellar advisory board behind us, we are poised for an exciting, quick, and successful launch. We promise a rapid and fair review and fast publication. We also welcome your suggestions and comments on ways we can make the journal better serve your needs."

Readership will include chemical engineers; biological engineers, biomolecular engineers, biomedical engineers and other engineers and scientists with interests in translational medicine, biotechnology, and biochemical and biomolecular engineering; and physicians and other healthcare researchers and professionals.

Additional information is available at: http://www.aiche.org/biotm or by email at biotm@aiche.org.

EDITORIAL ADVISORY BOARD:

--  Kristi Anseth, University of Colorado Boulder
--  Mark Davis, California Institute of Technology
-- Michael Deem, Rice University
-- Francis J. Doyle III, Harvard University
-- George Georgiou, University of Texas, Austin
--  Linda Griffith, Massachusetts Institute of Technology
--  Paula Hammond, Massachusetts Institute of Technology
--  Justin Hanes, Johns Hopkins University
-- Ravi Kane, Georgia Institute of Technology
-- Ali Khademhosseini, Harvard University
-- Chaitan Khosla, Stanford University
-- Cato Laurencin, University of Connecticut
--  Antonios Mikos, Rice University
-- Nicholas Peppas, University of Texas, Austin
-- Mark Prausnitz, Georgia Institute of Technology
-- W. Mark Saltzman, Yale University
-- David Schaffer, University of California, Berkeley
-- Gregory Stephanopoulos, Massachusetts Institute of Technology
-- David Tirrell, California Institute of Technology
-- Matthew Tirrell, University of Chicago
-- Jackie Ying, A*-STAR, Institute of Bioengineering and Nanotechnology

Wiley:
Dawn Peters (US) +1 781-388-8408
Tom Griffin (UK) +44 (0) 1865 476213
Email: sciencenewsroom@wiley.com  
Follow Wiley on Twitter @WileyNews                                     

AIChE:
Jeanette Krebs +1 717-214-2200
Email:  krebs@thebravogroup.com

 

SOURCE American Institute of Chemical Engineers



RELATED LINKS

http://www.aiche.org/biotm
http://www.aiche.org/biotm